api - Profile
✉ Email this page to a colleague
US Patents and Regulatory Information for api
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | ELIQUIS | apixaban | TABLET;ORAL | 202155-001 | Dec 28, 2012 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Hetero Labs Ltd V | APIXABAN | apixaban | TABLET;ORAL | 210066-002 | Nov 21, 2023 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Bristol | ELIQUIS SPRINKLE | apixaban | FOR SUSPENSION;ORAL | 220073-001 | Apr 17, 2025 | RX | Yes | Yes | 11,896,586*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Bristol Myers Squibb | ELIQUIS | apixaban | TABLET, FOR SUSPENSION;ORAL | 202155-003 | Apr 17, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Regcon Holdings | APIXABAN | apixaban | TABLET;ORAL | 209898-002 | Sep 11, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
